CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD70 CAR-T 治疗白血病：I 期临床试验（Baylor College of）

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

这是一项 I 期注册临床试验，评估细胞治疗用于白血病的安全性、可行性及初步疗效。当前状态：招募中。计划入组 78 例。试验地点：美国 · 休斯顿（共 2 个中心）。登记号：NCT06345027。

自相残杀效应降低的人源化 CD70 靶向 CAR-T 细胞对 AML 与 RCC 表现出强效抗肿瘤活性

Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.

寻找 AML 中安全有效的 CAR-T 靶点

The search for safe and effective CAR-T targets in AML.

CAR-T 与 CAR NK 细胞治疗急性髓系白血病的最新进展

Recent advances in CAR T and CAR NK cell therapy for AML.

将去甲基化药物与现货型 CD70 靶向嵌合抗原受体工程化自然杀伤 T 细胞协同用于治疗急性髓系白血病

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of a

急性髓系白血病 CAR-T 细胞治疗的新兴策略：通过双抗原靶向克服异质性并提高安全性

Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.

靶向 CD70 的 CAR-T/NK 治疗：原理、进展和未来方向

CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions.

靶向 CD70 与活化整合素 β2 的双顺反子 CAR-T 细胞克服急性髓系白血病中的抗原异质性并保持安全性

Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia.

战略创新：应对急性髓系白血病免疫治疗的挑战

Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.

分泌抗 CD33/抗 CD3 双靶向抗体的 CD70 CAR-T 细胞克服 AML 中的抗原异质性

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.